BYL719 , 98% , 1217486-61-7
CAS NO.：1217486-61-7
Empirical Formula: C19H22F3N5O2S
Molecular Weight: 441.47
MDL number: MFCD22417085
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB199.20 | In Stock |
|
| 5MG | RMB594.40 | In Stock |
|
| 10MG | RMB1095.20 | In Stock |
|
| 20MG | RMB1439.20 | In Stock |
|
| 50MG | RMB2983.20 | In Stock |
|
| 100mg | RMB4665.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Density | 1.391 |
| storage temp. | Store at -20°C |
| solubility | ≥22.07 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| form | White solid. |
| pka | 6.29±0.70(Predicted) |
| color | Off-white to light yellow |
| InChIKey | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| SMILES | N1(C(NC2=NC(C)=C(C3C=CN=C(C(C)(C)C(F)(F)F)C=3)S2)=O)CCC[C@H]1C(N)=O |
Description and Uses
BYL719 is an inhibitor of phosphoinositide 3-kinase α (PI3Kα; IC50s = 4.6, 4, and 4.8 nM for wild-type, E545K mutant, and H1047R mutant PI3K, respectively). It is selective for PI3Kα over PI3Kβ, PI3Kδ, PI3Kγ, and PI4Kβ (IC50s = 1,156, 290, 250, and 581 nM, respectively), as well as VPS34, mTOR, DNA-PK, and ATR (IC50s = >9,100 nM for all). BYL719 (12.5, 25, and 50 mg/kg) reduces tumor volume in a PI3Kα-dependent Rat1-myr-p110α mouse xenograft model. It also reduces tumor burden in THP-1 acute myeloid leukemia (AML) and MCF-7 breast cancer mouse xenograft models. Formulations containing BYL719 have been used in the treatment of advanced or metastatic breast cancer.
(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide is a newly developed phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor for the treatment of proliferative diseases.
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Danger |
| Hazard statements | H373 |
| Precautionary statements | P260-P314-P501 |
| HS Code | 29341000 |
